Insights into tumor suppression mechanism of miRNA-101 in medullary thyroid carcinoma

doi:10.12092/j.issn.1009-2501.2018.05.007

Abstract

Abstract:

AIM: To explore the tumor suppression mechanism of microRNA-101 in human medullary thyroid carcinoma cells (TT cells). METHODS: The expression of microRNA-101 in tissue samples from patients with medullary thyroid carcinoma was analyzed by quantitative RT-PCR. Then TT cells were divided into two groups and transfected with miRNA-101 mimics/ negative control. Flow cytometry and Transwell assay were used to detect TT cell cycle distribution, apoptotic rate as well as cell migration. Moreover, Western blot, flow cytometry, luciferase and Transwell assays were used to predict target gene of miRNA-101 as well as its underlying mechanism. RESULTS: MiRNA-101 was significantly down-regulated in medullary thyroid carcinoma tissues. MiRNA-101 mimics' transfection significantly inhibited TT cell proliferation and migration, induced cell apoptosis comparing with negative control. Western blot and luciferase assay revealed that SOX9 gene expression was down-regulated by miRNA-101. Silencing of SOX9 by siRNA showed similar effects with miRNA-101 over-expression. CONCLUSION: MicroRNA-101 inhibits proliferation, migration and induces apoptosis of human medullary thyroid carcinoma cells by targeting SOX9 gene.

Key words: medullary thyroid carcinoma cells, microRNA-101, SOX9

CLC Number:

R965.2

XU Ming, CUI Peng, YE Min, NI Xiong, WANG Tingfeng, MIN Zhijun. Insights into tumor suppression mechanism of miRNA-101 in medullary thyroid carcinoma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 524-530.

References

［1］Hazard JB, Hawk WK, Crile G Jr. Medullary (solid) carcinoma of the thyroid-a clinicopathologic entity［J］. J Clin Endocrinol Metab, 1959, 19(1): 152-161.
［2］黄彩平, 朱永学, 田敖龙. 147例甲状腺髓样癌临床分析［J］. 中华肿瘤杂志, 2003, 25(5): 490-492.
［3］Lee RC, Feinbaum RL, Ambros V,et al. Elegans heterochromic gene Lin-4 encodes small RNAs with antisense complementarity to Lin-14［J］. Cell, 1993, 75(5): 843-845.
［4］Kozomara A, GriffithsJones S. miRBase: annotating high confidence microRNAs using deep sequencing data［J］. Nucleic Acids Res, 2014, 42: 68-73.
［5］Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues［J］. Oncogene, 2006, 25(17): 2537-2545.
［6］Lowery A J, Miller N, Devaney A, et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER/neu receptor status in breast cancer［J］. Breast Cancer Res, 2009, 11(3): R27.
［7］Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis［J］. Cancer Cell. 2006, 9(3): 189-198.
［8］Ratert N, Meyer HA, Jung M, et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome［J］. J Mol Diagn. 2013, 15(5): 695-705.
［9］Corte H, Manceau G, Blons H, et al. MicroRNA and colorectal cancer［J］. Dig Liver Dis. 2012, 44(3): 195200.
［10］胡明珠, 李佩玲. 非编码RNA在卵巢癌中的研究进展［J］. 疑难病杂志, 2016, 15(11): 1197-1200, 1205.
［11］Abraham D, Jackson N, Gundara JS, et al. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets［J］. Clin Cnacer Res, 2011, 17(4): 4772-4781.
［12］Pennelli G, Galuppini F, Barollo S, et al. The PDCD4/miR-21 pathway in medullary thyroid carcinoma［J］. Hum Pathol. 2015, 46(1): 50-57.
［13］Hudson JH, Duncavage E, Tamburrino A, et al. Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma［J］. Exp Mol Pathol, 2013, 95(1): 62-67.
［14］Duan L, Hao X, Liu Z, et al. MiR-129-5p is down-regulated and involved in the growth, apoptosis and migration of medullary thyroid carcinoma cells through targeting RET［J］. FEBS Lett, 2014, 588(9): 1644-1651.
［15］Su H, Yang J R, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity［J］. Cancer Res, 2009, 69(3): 1135-1142.
［16］ Cho HM, Jeon HS, Lee SY, et al. microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2［J］. Exp Ther Med, 2011, 2(5): 963-967.
［17］Chakravarthi BVSK, Goswami MT, Pathi SS, et al. MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer［J］. Oncogene, 2016, 35(49): 6330-6340.
［18］Huang F, Lin C, Shi YH, et al. MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells［J］. Asian Pac J Cancer Prev, 2013, 14(10): 5915-5920.
［19］Long Y, Wu Z, Yang X, et al. MicroRNA-101 inhibits the proliferation and invasion of bladder cancer cells via targeting c-FOS［J］. Mol Med Rep, 2016, 14(3): 2651-2656.
［20］Wang C, Lu S, Jiang J, et al. HsamicroRNA101 suppresses migration and invasion by targeting Rac1 in thyroid cancer cells［J］. Oncology Lett, 2014, 8(4): 1815-1821.
［21］陈维, 王昌留, 王磊. SOX9基因的结构、功能及进化［J］. 生命的化学, 2012, 32(4): 310-315.
［22］Zhang Y, Guo X, Xiong L, et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma［J］. FEBS Lett, 2012, 586(24): 4362-4370.
［23］Liu N, Zhang L, Wang Z, et al. MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9［J］. Oncotarget, 2017, 8(12): 19244-19254.

[1]	CAO Xuefen, LENG Yufang, HAN Xiaoxia, HOU Xiaoyu, LYU Xingjiao, Janvier NIBARUTA. Tetramethylpyrazine protected against intestinal ischemia-reperfusion injury induced pyroptosis by inhibiting NLRP3 inflammasome activation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1201-1208.
[2]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[3]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[4]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[5]	SHI Dandan, SUN Yiyao, CHEN Xiaoqi, YANG Fangming, ZHANG Chuanlei, WANG Xinting, YUAN Changwei, CHEN Xinju. Curative effect of fuzheng xiaoliu granules in the treatment of primary liver cancer and analysis of serum metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1247-1262.
[6]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[7]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[8]	HENG Bingbing, YANG Danfeng, DAI Shuyang, SHANGGUAN Wangning. Propofol relieves the subcutaneous chloroquine-induced pruritus in rats via TRPV1 and CB1 receptors of spinal cord [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1101-1108.
[9]	LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
[10]	YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan. Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
[11]	WANG Ruyue, XIE Fei, WANG Xin, LI Hongyu. Therapeutic effect of lienal polypeptide injection on bone marrow suppression and immunodeficiency in KM mice following chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1000-1007.
[12]	MAO Jun, RONG Yu, LI Yangen, XIONG Dengxi, ZHAO Peng, ZHA Zhengjiang. Effect and safety of flurbiprofen axetil in the analgesic treatment of patients with craniocerebral injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1056-1060.
[13]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[14]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[15]	LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.